Who, when, and how to reverse non-vitamin K oral anticoagulants.

Aronis, Konstantinos N; Hylek, Elaine M

Aronis, Konstantinos N; Hylek, Elaine M.

Affiliation

Aronis KN; Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston University, Boston, MA, USA. dr.karonis@hotmail.com.
Hylek EM; Division of Cardiology, Johns Hopkins Hospital, Johns Hopkins University, Zayed 7122, 1800 Orleans St, Baltimore, MD, 21287, USA. dr.karonis@hotmail.com.

J Thromb Thrombolysis ; 41(2): 253-72, 2016 Feb.

Article in En | MEDLINE | ID: mdl-26627486

Subject(s)

Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Factor Xa; Recombinant Proteins; Antibodies, Monoclonal, Humanized/pharmacokinetics; Antibodies, Monoclonal, Humanized/therapeutic use; Anticoagulants/adverse effects; Anticoagulants/pharmacokinetics; Anticoagulants/therapeutic use; Antidotes/pharmacokinetics; Antidotes/therapeutic use; Factor Xa/pharmacokinetics; Factor Xa/therapeutic use; Humans; Recombinant Proteins/pharmacokinetics; Recombinant Proteins/therapeutic use; Vitamin K

Key words

Andexanet alfa; Antidotes; Aripazine; Idarucizumab; Non-vitamin K oral anticoagulants; Reversal

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Proteins / Factor Xa / Antibodies, Monoclonal, Humanized / Anticoagulants / Antidotes Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Thromb Thrombolysis Journal subject: ANGIOLOGIA Year: 2016 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google